Citadel Advisors’s Sunshine Biopharma SBFM Stock Holding History

Citadel Advisors’s Portfolio SBFM Stock Details SBFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,625	Closed	-$48.1K	–	14704
2026 Q1	$48.1K	Sell	4,625 -768	-14%	-$9.05K	﹤0.01%	12418
2025 Q4	$66.3K	Sell	5,393 -2,416	-31%	-$38.2K	﹤0.01%	11898
2025 Q3	$116K	Buy	7,809 +1,466	+23%	+$21.7K	﹤0.01%	11734
2025 Q2	$91.3K	Buy	+6,343	New	+$92.7K	﹤0.01%	11411
2024 Q2	–	Sell	-28	Closed	-$33.3K	–	15248
2024 Q1	$33.3K	Buy	28 +19	+211%	+$55.8K	﹤0.01%	12591
2023 Q4	$50.3K	Buy	+9	New	+$51.2K	﹤0.01%	11779

Other funds holding SBFM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SFG

Strive Financial Group Carmel, Indiana $230M AUM

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Citadel Advisors's SBFM Position: Q2 2026 in Review

Citadel Advisors sold out of Sunshine Biopharma (SBFM) in Q2 2026, closing a stake of 4,625 shares — an estimated $48.1K sold.

Citadel Advisors first reported a position in SBFM in Q4 2023 and held it in 6 quarters. The position peaked at $116K in Q3 2025. 9 funds tracked by Wall St. Rank hold SBFM as of Q2 2026.

Citadel Advisors reported no remaining Sunshine Biopharma position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 4,625 Sunshine Biopharma shares in Q2 2026, an estimated $48.1K.
Citadel Advisors first reported a position in Sunshine Biopharma in Q4 2023 and held it in 6 quarters.
Citadel Advisors's Sunshine Biopharma position peaked at $116K in Q3 2025.
9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.